Physician profile
Amanda Hall
NPI 1740741446
$1,555.19
in general payments reported to CMS, 2019-2025
12 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.29 · 2023: $896 · 2024: $296 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $800 · Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $800.00 |
| Food and Beverage | $697.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $904.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $135.32 | 2022-2025 | Tezspire, Fasenra |
| Grifols USA, LLC | $126.41 | 2024 | Xembify |
| Glaxosmithkline, LLC. | $97.10 | 2022-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $80.49 | 2025 | |
| Ionis Pharmaceuticals, INC. | $47.15 | 2025 | Dawnzera |
| Csl Behring | $45.77 | 2023-2024 | Hizentra, Haegarda |
| Biocryst US Sales Co., LLC | $29.26 | 2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $27.91 | 2024 | Dupixent |
| Pharming Healthcare, INC. | $24.58 | 2023 | Ruconest |
| Amgen INC. | $19.10 | 2025 | Actimmune |
| Galderma Laboratories, L.P. | $18.01 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.